Metformin enhances cytotoxic action of dichloroacetate against Lewis lung carcinoma cells in vitro


  • D.L. Kolesnik R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • O.N. Pyaskovskaya R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • O. Gorbach R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • G.I. Solyanik R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology



Lewis lung carcinoma, metformin, sodium dichloroacetate


Summary. Tumor cell metabolism is considered one of the hallmarks of cancer. This concept is exploited in the development of new ways of anticancer therapy based on the use of substances capable of changing drastically bioenergetic metabolism of tumor cells. Among them, sodium dichloroace­tate (DCA), an inhibitor of pyruvate dehydrogenase kinase, and metformin (MTF), an antidiabetic hypoglycemic drug, an inhibitor of the mitochondrial respiratory chain (complex I), both have been long used in clinical non-oncological practice, and presently are considered promising candidates in oncology. Aim: To study the capability of MTF to enhance the antitumor action of DCA against Lewis lung carcinoma cells in vitro. Materials and Methods: LLC/R9, a low metastatic variant of Lewis lung carcinoma cells, was used. Effects of 30 mM DCA in combination with 2 mM MTF on cell survival, cell cycle distribution, apoptosis, mitochondrial potential, intracellular ATP level, glucose consumption, and lactate production rates were determined in vitro. Results: MTF was shown to enhance the cytotoxic/cytostatic action of DCA against LLC/R9 cells in vitro. Treatment of LLC/R9 cells with 30 mM DCA in combination with 2 mM MTF resulted in a 39% decrease in the number of viable cells (p < 0.05), a 2.8-fold increase of the number of dead cells (p < 0.05), a near 2-fold decrease in the proportion of cells at the S-phase (p < 0.05), a 4-fold increase in the apoptosis (p < 0.05) and significant reduction (p < 0.05) of the mitochondrial membrane potential of tumor cells as compared to corresponding values in control. DCA alone reduced glucose consumption and lactate production rates by more than 26% (p < 0.05) and 34% (p < 0.05), respectively, whereas MTF counteracted these effects. Nevertheless, in the cells treated with both DCA and DCA in combination with MTF, the intracellular adenosine triphosphate increased by 33–35% compared with that in the control (p < 0.05). Conclusion: MTF enhanced the cytotoxic/cytostatic action of DCA against LLC/R9 cells in vitro, which points on their possible synergistic antitumor action in vivo.


Wilson PM, Danenberg PV, Johnston PG, et al. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nat Rev Clin Oncol 2014; 11: 282–98.

Jin S, DiPaola RS, Mathew R, White E. Metabolic catastrophe as a means to cancer cell death. J Cell Sci 2007; 120: 379–83.

Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 2011; 10: 671–84.

Jones NP, Schulze A. Targeting cancer metabolism–aiming at a tumour’s sweet-spot. Drug Discov Today 2012; 17: 232–41.

Zhang Y, Yang JM. Altered energy metabolism in cancer: a unique opportunity for therapeutic intervention. Cancer Biol Ther 2013; 14: 81–9.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646–74.

Yoshida GJ. Metabolic reprogramming: the emerging concept and associated therapeutic strategies. J Exp Clin Cancer Res 2015; 34: 111. doi: 10.1186/s13046-015-0221-y.

Morandi A, Indraccolo S. Linking metabolic reprogramming to therapy resistance in cancer. Biochim Biophys Acta Rev Cancer 2017; 1868: 1–6.

Bonnet S, Archer SL, Allalunis-Turner J, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007; 11: 37–51.

Madhok BM, Yeluri S, Perry SL, et al. Dichloroacetate induces apoptosis and cell-cycle arrest in colorectal cancer cells. Br J Cancer 2010; 102: 1746–52.

Kankotia S, Stacpoole PW. Dichloroacetate and cancer: new home for an orphan drug? Biochim Biophys Acta 2014; 1846: 617–29.

James MO, Jahn SC, Zhong G, et al. Therapeutic applications of dichloroacetate and the role of glutathione transferase zeta-1. Pharmacol Ther 2017; 170: 166–80.

Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000; 348: 607–14.

Fontaine E. Metformin-induced mitochondrial complex I inhibition: facts, uncertainties, and consequences. Front Endocrinol (Lausanne) 2018; 9: 753. doi: 10.3389/fendo.2018.00753. eCollection 2018.

Yudhani RD, Astuti I, Mustofa M, et al. Metformin modulates cyclin D1 and p53 expression to inhibit cell prolife­ration and to induce apoptosis in cervical cancer cell lines. Asian Pac J Cancer Prev 2019; 20: 1667–73.

Pusapati RV, Daemen A, Wilson C, et al. mTORC1-dependent metabolic reprogramming underlies escape from glycolysis addiction in cancer cells. Cancer Cell 2016; 29: 548–62.

Cacace A, Sboarina M, Vazeille T, Sonveaux P. Glutamine activates STAT3 to control cancer cell proliferation independently of glutamine metabolism. Oncogene 2017; 36: 2074–84.

Gang BP, Dilda PJ, Hogg PJ, Blackburn AC. Targeting of two aspects of metabolism in breast cancer treatment. Cancer Biol Ther 2014; 15: 1533–41.

Haugrud AB, Zhuang Y, Coppock JD, Miskimins WK. Dichloroacetate enhances apoptotic cell death via oxidative damage and attenuates lactate production in metformin-treated breast cancer cells. Breast Cancer Res Treat 2014; 147: 539–50.

Li B, Li X, Ni Z, et al. Dichloroacetate and metformin synergistically suppress the growth of ovarian cancer cells. Oncotarget 2016; 7: 59458–70.

Kolesnik DL, Pyaskovskaya ON, Yurchenko OV, Solyanik GI. Metformin enhances antitumor action of sodium dichloroacetate against glioma C6. Exp Oncol 2019; 41: 123–9.

Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nature Protocol 2006; 1: 1112–6.

Nicoletti I, Migliorati G, Pagliacci MC, et al. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139: 271–80.

Sena P, Mancini S, Benincasa M, et al. Metformin induces apoptosis and alters cellular responses to oxidative stress in Ht29 colon cancer cells: Preliminary findings. Int J Mol Sci 2018; 19: 1478. doi:10.3390/ijms19051478.

Lee J, Hong EM, Kim JH, et al. Metformin induces apoptosis and inhibits proliferation through the AMP-activated protein kinase and insulin-like growth factor 1 receptor pathways in the bile duct cancer cells. J Cancer 2019; 10: 1734–44.

Yadav N, Kumar S, Marlowe T, et al. Oxidative phosphorylation-dependent regulation of cancer cell apoptosis in response to anticancer agents. Cell Death Dis 2015; 6: e1969. doi: 10.1038/cddis.2015.305.

Mitra K, Wunder C, Roysam B, et al. A hyperfused mitochondrial state achieved at G1–S regulates cyclin E buildup and entry into S phase. Proc Natl Acad Sci USA 2009; 106: 11960–5.

Bao Y, Mukai K, Hishiki T, et al. Energy management by enhanced glycolysis in G1-phase in human colon cancer cells in vitro and in vivo. Mol Cancer Res 2013, 11: 973–85.

Choi YK, Park. K-G. Metabolic roles of AMPK and metformin in cancer cells. Mol Cells 2013; 36: 279–87.

Marín-Hernández A, Gallardo-Pérez JC, Ralph SJ, et al. HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem 2009; 9: 1084–101.

Nagao A, Kobayashi M, Koyasu S, et al. HIF-1-dependent reprogramming of glucose metabolic pathway of cancer cells and its therapeutic significance. Int J Mol Sci 2019; 20: 238. doi: 10.3390/ijms20020238.

Kolesnik DL, Pyaskovskaya ON, Yakshibaeva YuR, Solyanik G.I. Time-dependent cytotoxicity of dichloroacetate and metformin against Lewis lung carcinoma. Exp Oncol 2019, 41: 14–9.

Ma L, Wei J, Wan J, et al. Low glucose and metformin-induced apoptosis of human ovarian cancer cells is connected to ASK1 via mitochondrial and endoplasmic reticulum stress-associated pathways. J Exp Clin Cancer Res 2019; 38: 77.

Hwang SH, Kim MC, Ji S, et al. Glucose starvation induces resistance to metformin through the elevation of mitochondrial multidrug resistance protein 1. Cancer Sci 2019; 110: 1256–67.

Kolesnik DL, Pyaskovskaya ON, Solyanik GI. Impact of lactic acidosis on the survival of Lewis lung carcinoma cells. Exp Oncol 2017, 39: 112–6.

Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167–74.




How to Cite

Kolesnik, D., Pyaskovskaya, O., Gorbach, O., & Solyanik, G. (2023). Metformin enhances cytotoxic action of dichloroacetate against Lewis lung carcinoma cells in vitro. Experimental Oncology, 42(1), 35–39.



Original contributions

Most read articles by the same author(s)